<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_Munich_Applied_Design skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:Munich/Applied Design</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><P><B style=" color: #ffffff !important">-_-</B></P></DIV><DIV class="dropdown"><BUTTON class="dropbtnProject dropbtn"><A href="/Team:Munich/Description"><P><B>Project</B></P></A></BUTTON><DIV class="dropdown-contentDescription dropdown-content"><A href="/Team:Munich/Description"><P><B>Description</B></P></A></DIV><DIV class="dropdown-contentDesign dropdown-content"><A href="/Team:Munich/Design"><P><B>Design</B></P></A></DIV><DIV class="dropdown-contentDemonstration dropdown-content"><A href="/Team:Munich/Demonstrate"><P><B>Demonstrate</B></P></A></DIV><DIV class="dropdown-contentMeasurement dropdown-content"><A href="/Team:Munich/Measurement"><P><B>Measurement</B></P></A></DIV><DIV class="dropdown-contentApplication dropdown-content"><A href="/Team:Munich/Applied_Design"><P><B>Applied Design</B></P></A></DIV><DIV class="dropdown-contentFinalResults dropdown-content"><A href="/Team:Munich/Results"><P><B>Final Results</B></P></A></DIV><DIV class="dropdown-contentAchievements dropdown-content"><A href="/Team:Munich/Achievements"><P><B>Achievements</B></P></A></DIV></DIV><DIV class="dropdown" valign="center"><BUTTON class="dropbtnWetlab dropbtn" valign="center"><A href="/Team:Munich/Protocols"><P><B>Wetlab</B></P></A></BUTTON><DIV class="dropdown-contentProtocolsMethods dropdown-content"><A href="/Team:Munich/Protocols"><P><B>Protocols</B></P></A></DIV><DIV class="dropdown-contentLabJournal dropdown-content"><A href="/Team:Munich/Notebook"><P><B>Notebook</B></P></A></DIV><DIV class="dropdown-contentSafety dropdown-content"><A href="/Team:Munich/Safety"><P><B>Safety</B></P></A></DIV><DIV class="dropdown-contentParts dropdown-content"><A href="/Team:Munich/Parts"><P><B>Parts</B></P></A></DIV><DIV class="dropdown-contentImprove dropdown-content"><A href="/Team:Munich/Improve"><P><B>Improved Part</B></P></A></DIV><DIV class="dropdown-contentCollection dropdown-content"><A href="/Team:Munich/Part_Collection"><P><B>Part Collection</B></P></A></DIV><DIV class="dropdown-contentInterlab dropdown-content"><A href="/Team:Munich/InterLab"><P><B>InterLab</B></P></A></DIV></DIV><DIV class="dropdown"><BUTTON class="dropbtnModel dropbtn"><A href="/Team:Munich/Model"><P><B>Model/Software</B></P></A></BUTTON><DIV class="dropdown-contentModel dropdown-content"><A href="/Team:Munich/Model"><P><B>Model</B></P></A></DIV><DIV class="dropdown-contentSoftware dropdown-content"><A href="/Team:Munich/Software"><P><B>Software</B></P></A></DIV><DIV class="dropdown-contentSoftwareCollaborations dropdown-content"><A href="/Team:Munich/Software/Collaborations"><P><B>Collaboration</B></P></A></DIV></DIV><DIV class="dropdown"><BUTTON class="dropbtnSoftHardware dropbtn"><A href="/Team:Munich/Hardware"><P><B>Hardware</B></P></A></BUTTON><DIV class="dropdown-contentDetector dropdown-content"><A href="/Team:Munich/Hardware/Detector"><P><B>Detector</B></P></A></DIV><DIV class="dropdown-contentQuakeValve dropdown-content"><A href="/Team:Munich/Hardware/QuakeValve"><P><B>Quake Valve</B></P></A></DIV><DIV class="dropdown-contentPaperstrips dropdown-content"><A href="/Team:Munich/Hardware/Paperstrip"><P><B>Paperstrips</B></P></A></DIV><DIV class="dropdown-contentPCRChip dropdown-content"><A href="/Team:Munich/Hardware/SampleProcessing"><P><B>Sample Processing</B></P></A></DIV></DIV><DIV class="dropdown"><BUTTON class="dropbtnHP dropbtn"><A href="/Team:Munich/HP/Silver"><P><B>Human Practices</B></P></A></BUTTON><DIV class="dropdown-contentHPSilver dropdown-content"><A href="/Team:Munich/HP/Silver"><P><B>Silver</B></P></A></DIV><DIV class="dropdown-contentIHPgold dropdown-content"><A href="/Team:Munich/HP/Gold_Integrated"><P><B>Gold</B></P></A></DIV><DIV class="dropdown-contentPublicEngagement dropdown-content"><A href="/Team:Munich/Engagement"><P><B>Engagement</B></P></A></DIV><DIV class="dropdown-contentCollaborations dropdown-content"><A href="/Team:Munich/Collaborations"><P><B>Collaborations</B></P></A></DIV></DIV><DIV class="dropdown"><BUTTON class="dropbtnTeam dropbtn"><A href="/Team:Munich/Team"><P><B>Team</B></P></A></BUTTON><DIV class="dropdown-contentTeamMembers dropdown-content"><A href="/Team:Munich/Team"><P><B>Team members</B></P></A></DIV><DIV class="dropdown-contentSponsors dropdown-content"><A href="/Team:Munich/Sponsors"><P><B>Sponsors</B></P></A></DIV><DIV class="dropdown-contentAttributions dropdown-content"><A href="/Team:Munich/Attributions"><P><B>Attributions</B></P></A></DIV><DIV class="dropdown-contentGallery dropdown-content"><A href="/Team:Munich/Gallery"><P><B>Gallery</B></P></A></DIV></DIV><TABLE width="100%" height="100%" cellpadding="0" cellspacing="0" border="0"><TBODY><TR><TD colspan="6" align="left" valign="center"><FONT size="7" color="#51a7f9"><B style="color: #51a7f9; margin-top: 40px;">Applied Design</B></FONT></TD></TR><TR><TD colspan="6" align="center" valign="center"><H1>Diagnosis of infectious diseases and public health</H1><P>  
Traditionally, infectious diseases are diagnosed by cell culture or PCR-based methods. As these techniques require expensive infrastructure, trained personal, and time, the current practice suffers from three main problems. First, diagnosis is not available everywhere, and therefore pathogens are usually detected in central clinics<SUP><A class="myLink" href="#ref_2">2</A></SUP>, rather than at the point-of-care (POC). Second, diagnosis is not accessible to everyone. Especially in developing countries proper medical supply is often lacking, due to the high costs. And third, diagnosis is not available within a few hours, which can lead to negligence of laboratory tests, resulting in premature prescription of antibiotics, the primary reason for the recrudescence of resistant bacteria strains<SUP><A class="myLink" href="#ref_3">3</A></SUP>.</P></TD></TR><TR><TD colspan="6" align="center" valign="center"><H1>Current solutions for rapid testing</H1><P>  
Most point-of-care tests that are currently established on the market, like pregnancy tests, are based on antibodies targeting certain metabolites<SUP><A class="myLink" href="#ref_4">4</A></SUP>. These tests are therefore restricted to one specific application and require long and expensive design cycles for the development of new tests for other applications or changing pathogen epitopes as in case of endemic virus strains with high mutation rate.
</P><P>
According to our contact person at Médecins Sans Frontières (<A class="myLink" href="http://msf.org">MSF</A>), already existing low-cost POC-test for infectious diseases are mostly based on antibody-based lateral flow tests such as  <A class="myLink" href="http://www.biomerieux-diagnostics.com/bionexia-rota-adeno-rapid-test">BIONEXIA® Rota Adeno</A> or <A class="myLink" href="http://nhdiag.com/cholera_bt.shtml">SMART™II Cholera O1</A>. Recently, qPCR-based systems were developed that provide a more universal solution for highly automated nucleic-acid detection. According to our contact person at MSF, also cartridge-based systems  are currently employed as POC diagnostics for in-field applications. <A class="myLink" href="http://www.cepheid.com/us/cepheid-solutions/systems/genexpert-systems/genexpert-iv">GeneXpert</A> allows the  detection of MRSA in patient samples, and <A class="myLink" href="https://www.alere.com/en/home/search.html?searchtext=alereq&amp;c=WW&amp;%3Acq_csrf_token=undefined">Alere™ q</A> provides an automated bench top platform for nucleic acid testing in any healthcare setting. 
</P><P>
These qPCR- and ELISA-based methods represent a significant advance in the portability and usability of point-of-care testing. However, these tests include plenty of plastic waste and cost around 10$ for consumables and several thousands of dollars for the main device. This is too high for applications in developing countries for which doctors without borders calls a price of less than 1$ per test.
</P></TD></TR><TR><TD colspan="6" align="center" valign="center"><H1>CascAID as an ultimate solution</H1><P>  
We developed CascAID to combine the portability, affordability, and usability of point-of-care tests with the universality and sensitivity of PCR-based nucleic acid detection. We achieve this by using the tools of synthetic biology to minimize hardware requirements and by supplying CascAID in a low-cost paper-based format.
Due to the rapid, software-aided design of crRNA, CascAID can be easily adapted to a variety of targets - from bacterial infections and rapidly evolving viral epidemics to cancer-associated mutations. 
Additionally, the Cas13a enzyme was shown to find targets with a single-nucleotide specificity, superior to PCR-based methods<SUP><A class="myLink" href="#ref_1">1</A></SUP>. CascAID can be entirely conducted on-site by the doctor or patient and therefore reduces the logistic complexity, drastically hastening the diagnostic process.
</P></TD></TR><TR><TD colspan="6" align="center" valign="center"><H1>Impact on lives</H1><P>  
With CascAID we venture to solve global health challenges and therefore impact the lives of people living in the developed world, as well as developing countries.
</P></TD></TR><TR><TD class="verticalColumn" colspan="3" align="center" valign="center"><H3>Global epidemics</H3><P>  
CascAID can be made available everywhere. Due to its small size and little infrastructure requirements, CascAID can be used in mobile health-stations visiting remote areas, lacking a centralized healthcare system. This minimizes the travel expenses of patients living far from hospitals and therefore aids to receive a timely cure. As CascAID can be rapidly customized to fit local variants of pathogens, it is applicable in any region on the globe. By employing it as a safety test at airports, it would assist in containing the spread of potential global epidemics like Ebola, Zika, or the plague. 
</P></TD><TD class="verticalColumn" colspan="3" align="center" valign="center"><H3>At home testing</H3><P>
CascAID is accessible to everyone. Designed with an open-source philosophy, the hardware, like our fluorescence detector Lightbringer, can be assembled from common low-cost components by anyone. We did a poll, to address the question of whether people would use CascAID to diagnose themselves for infectious diseases at home, without going to a doctor. Although we received a good resonance from the public, we think that a universal tool for nucleic acid testing is very powerful and therefore raises ethical issues. If applied for detection of, e.g., severe genetic diseases or HIV, the presence of a doctor is also essential for guidance and psychological aid, which is why usage of such tests must be debated and regulated appropriately. More information on risks of self-tests can be found on our <A class="myLink" href="https://2017.igem.org/Team:Munich/Safety">Safety page</A>.
</P></TD></TR><TR><TD class="verticalColumn" colspan="3" align="center" valign="center"><H3>Antibiotics resistance</H3><P>  
CascAID is fast and high-sensitive. This is crucial to enable a timely and appropriate therapy. For instance, the ability to distinguish between viral and bacterial infections would be of great importance for lowering antibiotics over-prescription. This way a misuse of antibiotics as a leading reason for multi-resistant bacteria strains would be significantly reduced.
</P></TD><TD class="verticalColumn" colspan="3" align="center" valign="center"><H3>Spin-offs</H3><P>
Finally, as CascAID is a modular platform, single parts can be used as a spin-off. For instance, our detector could serve as a tool to measure kinetics of biological or chemical reactions, that is available to other iGEM teams or research laboratories.</P></TD></TR><TR><TD colspan="6" align="center" valign="center"><H3>References</H3><P><OL style="text-align: left"><LI id="ref_1">Gootenberg, J. S., et al. (2017). &quot;Nucleic acid detection with CRISPR-Cas13a/C2c2.&quot; <I>Science</I> 356(6336): 438-442.
</LI><LI id="ref_2">St John, A. and C. P. Price (2014). &quot;Existing and Emerging Technologies for Point-of-Care Testing.&quot; <I>Clin Biochem Rev</I> 35(3): 155-167.
</LI><LI id="ref_3">Llor, C., &amp; Bjerrum, L. (2014). &quot;Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem.&quot; <I>Therapeutic Advances in Drug Safety</I>, 5(6), 229–241.</LI><LI id="ref_4">Peeling, R. W. and R. McNerney (2014). &quot;Emerging technologies in point-of-care molecular diagnostics for resource-limited settings.&quot; <I>Expert Rev Mol Diagn</I> 14(5): 525-534.</LI></OL></P></TD></TR></TBODY></TABLE></DIV></DIV></DIV></DIV></BODY></HTML>